Evidence map›Paper›PMID 36588538›Full record

ArticleBioMed research international2022

Identification of an Immune-Related Gene Signature Associated with Prognosis and Tumor Microenvironment in Esophageal Cancer.

Chunzhen Li, Weizheng Zhou, Ji Zhu, Qi Shen, Guangjie Wang, Ling Chen, Tiejun Zhao

Abstract read
In one paragraph

Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. miRNA profiling of esophageal adenocarcinoma using transcriptome analysis.Cancer biomarkers : section A of Disease markers · 2024
    Article
  7. Article
  8. HSV: The scout and assault for digestive system tumors.Frontiers in molecular biosciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chunzhen LiSchool of Basic Medicine, Naval Medical University, Shanghai 200433, China.ORCID https://orcid.org/0000-0002-4223-0360
Weizheng ZhouDepartment of Thoracic Surgery, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China.
Ji ZhuDepartment of Thoracic Surgery, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China.
Qi ShenSchool of Basic Medicine, Naval Medical University, Shanghai 200433, China.
Guangjie WangSchool of Basic Medicine, Naval Medical University, Shanghai 200433, China.
Ling ChenDepartment of Thoracic Surgery, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China.ORCID https://orcid.org/0000-0001-8561-3612
Tiejun ZhaoDepartment of Thoracic Surgery, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China.ORCID https://orcid.org/0000-0002-8143-1149

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Esophageal cancer (EC) is a common malignant tumor of the digestive system with high mortality and morbidity. Current evidence suggests that immune cells and molecules regulate the initiation and progression of EC. Accordingly, it is necessary to identify immune-related genes (IRGs) affecting the biological behaviors and microenvironmental characteristics of EC. Methods: Bioinformatics methods, including differential expression analysis, Cox regression, and immune infiltration prediction, were conducted using R software to analyze the Gene Expression Omnibus (GEO) dataset. The Cancer Genome Atlas (TCGA) cohort was used to validate the prognostic signature. Patients were stratified into high- and low-risk groups for further analyses, including functional enrichment, immune infiltration, checkpoint relevance, clinicopathological characteristics, and therapeutic sensitivity analyses. Results: A prognostic signature was established based on 21 IRGs (S100A7, S100A7A, LCN1, CR2, STAT4, GAST, ANGPTL5, TRAV39, F2RL2, PGLYRP3, KLRD1, TRIM36, PDGFA, SLPI, PCSK2, APLN, TICAM1, ITPR3, MAPK9, GATA4, and PLAU). Compared with high-risk patients, better overall survival rates and clinicopathological characteristics were found in low-risk patients. The areas under the curve of the two cohorts were 0.885 and 0.718, respectively. Higher proportions of resting CD4 Conclusion: Our immune-related signature yielded reliable value in evaluating the prognosis, microenvironmental characteristics, and therapeutic sensitivity of EC and may help with the precise treatment of this patient population.

Indexed as

Esophageal NeoplasmsTumor MicroenvironmentHumansOX40 LigandPrognosisOX40 LigandTNFSF4 protein, human

Identifiers

PMID36588538
PMCPMC9803573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.